Abstract: An assembly may include first and second components and a service flange. The first component has a first opening. The second component has a second opening in communication with the first opening. The service flange may be mounted to the first component such that the first component is disposed between the service flange and the second component. The service flange extends around the periphery of the first opening and may include a plurality of separate and discrete segments that are individually secured to the first component. Adjacent segments define joints that movably connect the segments together while allowing for relative movement between the segments before the first component is secured to the second component. The segments include mounting apertures spaced apart from the joints and receiving fasteners configured to fixedly secure the first component to the second component. Each fastener only engages a single segment of the service flange.

Abstract: An assembly may include first and second components and a service flange. The first component has a first opening. The second component has a second opening in communication with the first opening. The service flange may be mounted to the first component such that the first component is disposed between the service flange and the second component. The service flange extends around the periphery of the first opening and may include a plurality of separate and discrete segments that are individually secured to the first component. Adjacent segments define joints that movably connect the segments together while allowing for relative movement between the segments before the first component is secured to the second component. The segments include mounting apertures spaced apart from the joints and receiving fasteners configured to fixedly secure the first component to the second component. Each fastener only engages a single segment of the service flange.

Abstract: The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11; and/or an antibody VL domain selected from the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated in liver fibrosis.

Abstract: The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11; and/or an antibody VL domain selected front the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated it liver fibrosis.

Abstract: The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11; and/or an antibody VL domain selected front the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated it liver fibrosis.